Next Science Limited
NXSCF
Other OTC0.00
USD
-0.01
- -
ISIN
AU0000041329
Return %
Stock
S&P500
1Y
-98.57
26.53
3Y
-99.78
76.60
5Y
-99.90
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Matthew Franco Myntti
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- The Zenith Building, Tower A Sydney NSW Australia 2067
- IPO Date
- Jan 8, 2021
- Website
- nextscience.com
- Similar Companies
- Business
- Next Science Limited (ASX: NXS; OTC: NXSCF) is an Australia-based medical technology company that develops and commercializes proprietary XBIO technology to reduce the impact of biofilm-based infections in human health; XBIO is a non-toxic solution effective against both biofilm-based and free-floating bacteria. The company offers XPERIENCE advanced surgical irrigation for intraoperative cleansing to prevent surgical site infections; BLASTX antimicrobial wound gel for chronic and acute wound management; SurgX sterile antimicrobial gel for post-surgical incision protection with sustained effectiveness up to five days; and Bactisure surgical lavage for orthopedic procedures involving implants, distributed via partnerships such as Zimmer Biomet. Founded in 2012 through the efforts of Dr. Matthew Myntti and listed on the ASX in 2019, Next Science Limited maintains headquarters at Level 14, Australia Square, 264-278 George Street, Sydney NSW 2000, Australia, with commercial operations centered in Jacksonville, Florida, USA, and derives the majority of revenue from North America alongside sales in Australia and New Zealand. In September 2025, the company completed the sale of substantially all assets related to its core product lines—including regulatory approvals, intellectual property, inventory, contracts, records, and goodwill, excluding the durable medical equipment business—to OSARTIS GmbH (initially announced with Demetra Holding SpA) for US$50 million in cash, following a competitive process advised by Piper Sandler & Co; net proceeds of approximately US$30 million are earmarked for distribution to shareholders after debt repayment, transaction costs, and wind-down expenses, with transitional supply and license agreements in place to support the retained DME business.